Asian Investment Conference 2021
Chief Medical Officer, Genetron Health
Yunfu Hu is Chief Medical Officer at Genetron Health.
Prior to Genetron Health, Dr. Hu had served for more than 10 years at the US Food and Drug Administration (FDA) where his last role was Deputy Director at the Division of Molecular Genetics and Pathology, Office of In-Vitro Diagnostics (IVD) and Radiological Health. His team led the pre-market approval of many innovative IVD and laboratory-developed test (LDT) devices for cancer diagnostics and screening in the US. Some of the notable authorizations by Dr. Hu’s group at FDA include – the first next-generation sequencing (NGS)-based LDT as CDx (FoundationOne CDx); the first NGS-based CDx kit (Thermo Fisher Oncomine); the first NGS-based LDT for tumor profiling (MSK-IMPACT, and later, FoundationOne CDx); the first liquid biopsy test for non-small-cell lung carcinoma (NSCLC) (Cobas EGFR v2); and FDA’s only two approved cancer screening tests in the last decade – Exact Sciences Colonguard and Epigenomics Epi ProColon.
Prior to joining FDA, Dr. Hu had more than 10 years of product development experience in diagnostic and pharmaceutical industries, including his previous employments at GlaxoSmithKline and Becton Dickinson Diagnostic Systems.
Dr. Hu received his Ph.D. degree in Veterinary Physiology & Pharmacology from The Ohio State University in 1994, followed by a postdoctoral cancer research fellowship at Fox Chase Cancer Center. Dr. Hu has four US patents and over 30 publications.